The Relative Strength (RS) Rating for NewAmsterdam Pharma climbed into a new percentile Thursday, with an increase from 80 to 86.
Hone Your Stock-Picking Skills By Focusing On These Factors
IBD's unique rating tracks share price movement with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the last 52 weeks holds up against all the other stocks in our database.
History shows that the best stocks tend to have an RS Rating north of 80 as they launch their biggest runs.
NewAmsterdam Pharma is working on a consolidation with a 27.29 entry. See if the stock can break out in heavy trade.
NewAmsterdam Pharma reported 0% earnings growth in its most recent report, while sales growth came in at 825%.
NewAmsterdam Pharma earns the No. 21 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Rigel Pharmaceuticals and Incyte are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
